🧬
CRISPRO
.AI
HOME
BLOG
MANUSCRIPTS
RECEIPTS
PRODUCT
A+
CONFIRM CERTAINTY
NAVIGATE
HOME
BLOG
All posts
MANUSCRIPTS
All manuscripts
RECEIPTS · TRIAL CASES
LATIFY
NCT05450692 · Ceralasertib (ATRi) + Durvalumab (PD-L1) · IO-refractory NSCLC
CEACAM5
NCT04154956 · Tusamitamab Ravtansine (CEACAM5 ADC) · NSCLC
ADAVOSERTIB
NCT03579316 · Adavosertib (WEE1i) + Gemcitabine · Recurrent solid tumors (ovarian focus)
CAPRI
NCT02264678 · Ceralasertib (ATRi) + Olaparib (PARPi) · Recurrent HGSOC
BERZOSERTIB
NCT02595892 · Berzosertib (ATRi) + Gemcitabine · Platinum-resistant ovarian carcinoma
PRODUCT
TARGET LOCK
AUC 0.68
MOA ALIGN
8D Vector
SL ENGINE
d = −0.88
PGX
100% CPIC
Back
Open PDF
Loading manuscript…